Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosisRoss L. Levine, D. Gary Gilliland, Ayalew Tefferi et al.|Cancer Cell|2005Cited by 3k
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>Jyoti Nangalia, Anthony R. Green, Elli Papaemmanuil et al.|New England Journal of Medicine|2013Cited by 1.7k
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemiaMark A. Dawson, Tony Kouzarides, Rab K. Prinjha et al.|Nature|2011Cited by 1.5k
A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid LeukemiaKonstantinos Tzelepis, Kosuke Yusa, Hiroko Koike-Yusa et al.|Cell Reports|2016Cited by 834
Molecular, clinical, and therapeutic determinants of outcome in <i>NPM1</i>-mutated AMLJad Othman, Richard Dillon, Nicola Potter et al.|Blood|2024Cited by 78